Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
09/15/2020 09/16/2020 09/17/2020 09/18/2020 09/21/2020 Date
0.15(c) 0.14(c) 0.135(c) 0.13(c) 0.135(c) Last
384 963 369 650 299 750 272 000 163 200 Volume
0.00% -6.67% -3.57% -3.70% +3.85% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -6,80 M -5,11 M -5,11 M
Net Debt 2020 - - -
P/E ratio 2020 -6,56x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -15,6 M -11,7 M -11,7 M
Net Debt 2021 - - -
P/E ratio 2021 -3,28x
Yield 2021 -
Capitalization 37,7 M 28,3 M 28,3 M
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees -
Free-Float 85,5%
More Financials
Company
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and... 
More about the company
All news about PROMIS NEUROSCIENCES, INC.
09/10PROMIS NEUROSCIENCES : to Participate in H.C. Wainwright & Co. 22nd Annual Inves..
AQ
09/10PROMIS NEUROSCIENCES : to Participate in H.C. Wainwright & Co. 22nd Annual Inves..
AQ
09/10ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Inve..
GL
08/13ProMIS Neurosciences Announces Second Quarter 2020 Results
GL
08/11PROMIS NEUROSCIENCES : CEO memorandum to ProMIS shareholders, August 11, 2020
PU
07/29ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
GL
07/10PROMIS NEUROSCIENCES : and BC Neuroimmunology announce revenue-sharing joint ven..
AQ
07/09ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint ve..
GL
06/24ProMIS Neurosciences announces adjournment and change of location of annual m..
GL
06/17ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant..
GL
05/28ProMIS Neurosciences and collaborative team receive Supercluster Award suppor..
GL
05/21PROMIS NEUROSCIENCES : Chairman's Update details new programs from expanded use ..
AQ
05/20PROMIS NEUROSCIENCES : and BC Neuroimmunology expand collaboration to develop an..
AQ
05/20PROMIS NEUROSCIENCES : Chairman's Memorandum, May 20, 2020
PU
05/20ProMIS Neurosciences Chairman's Update details new programs from expanded use..
GL
More news
News in other languages on PROMIS NEUROSCIENCES, INC.

- No features available -

More news
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 2,44 $
Last Close Price 0,10 $
Spread / Highest target 4 129%
Spread / Average Target 2 376%
Spread / Lowest Target 623%
EPS Revisions
Managers
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
James Kupiec Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.-23.53%29
GILEAD SCIENCES, INC.0.11%81 555
VERTEX PHARMACEUTICALS21.21%69 125
REGENERON PHARMACEUTICALS47.87%58 428
WUXI APPTEC CO., LTD.44.70%33 862
GENMAB A/S64.16%25 314